Discovery of antiviral inhibitors of Ebola virus replication
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 5R43AI152672-02
Grant search
Key facts
Disease
EbolaStart & end year
20202022Known Financial Commitments (USD)
$300,000Funder
National Institutes of Health (NIH)Principal Investigator
INVESTIGATOR Glen CoburnResearch Location
United States of AmericaLead Research Institution
VENATORX PHARMACEUTICALS, INC.Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
Innovation
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Ebola viruses (EBOV) cause severe illnesses in humans with a high rate of mortality that approaches 90%. Novel therapies with potent and selective activity against EBOV are urgently needed for the prevention and treatment of Ebola virus disease (EVD). We propose to execute an innovative high throughput screening campaign using a unique reverse genetics system. This screen is expected to yield new inhibitors targeting EBOV replication that will serve as starting points for medicinal chemistry hit-to-lead efforts. If successful, we will deliver one or more new lead series targeting EBOV infection.